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ABSTRACT
Severe acute respiratory syndrome (SARS) is an infectious disease with a high mortality rate. Because SARS suddenly disappeared
after an approximately 1-year-long pandemic period (November 2002 to July 2003), insufficient data was available for the development of
in vitro diagnostics for SARS (SARS IVD). To rapidly identify cases in the event of future epidemics, it is necessary to establish a SARS
serological panel. In this study, 20 SARS convalescent sera and 20 normal sera from the Taiwan CDC were used to establish a SARS serological panel. This can be used as a standard for the Taiwan FDA to evaluate the effectiveness of SARS IVDs during the premarket approval
process. To characterize the immunological activity, protein extracts containing SARS coronavirus (SARS-CoV) proteins, synthetic viral
peptide fragments and recombinant viral proteins, were used to detect antibody reactivity. Results demonstrated that synthetic S, M, N
peptide fragments and whole SARS-CoV protein extracts had stronger antigenicity than individual recombinant viral proteins. Moreover,
results of the ELISA and the immunofluorescence assay indicated that our SARS panel had no cross-reactivity with the human coronavirus
229E, and displayed weak cross-reactivity with human coronavirus OC43. These findings suggested that our SARS serological panel is
suitable for evaluating SARS IVDs.
Key words: severe acute respiratory syndrome, serological panel, SARS coronavirus protein, human coronavirus 229E, human coronavirus OC43

Introduction
A worldwide outbreak of severe acute respiratory
syndrome was first reported in China in late 2002. The
disease was eventually termed “SARS” by the World Health
Organization (WHO) in 2003. The SARS outbreak resulted
in over 8,000 cases of infection with 10% mortality rate(1).
The etiological agent of SARS is a novel coronavirus named
SARS-CoV(2). The common human coronavirus strains 229E
(HCoV-229E) and OC43 (HCoV-OC43) cause upper respiratory tract infections, but SARS-CoV infects the lower respiratory tract, causing fever, cough without phlegm, headache,
hypoxemia, dyspnea, and eventually death from respiratory
failure(3). The SARS-CoV virion, similar to other coronaviruses, is composed of a spike (S) glycoprotein, a small
envelope (E) glycoprotein, a membrane (M) glycoprotein,
a nucleocapsid (N) phosphoprotein, and a hemagglutininacetylesterase (HA) glycoprotein. All of these proteins
play a critical role in the viral infection process. S protein
* Author for correspondence. Tel: 886-2-2787-7750;
Fax: 886-2-2787-7799; E-mail: dywang@fda.gov.tw

is responsible for receptor binding and can fuse the viral E
protein to host cells. E protein is a viroporin involved in virus
morphogenesis and budding. M protein, a typical transmembrane glycoprotein, is the most abundant structural protein
in the SARS virion. Evidence indicates that N protein can
block IFN-β production during the very early stage of infection(4-11). These proteins not only serve as markers of virus
infection but also act as potential targets for antiviral drug
discovery(12).
The SARS diagnostic methods, announced by WHO,
posed a number of challenges. For example, all procedures
for SARS-CoV culture had to be performed in biosafety
level 3 containment because of the high infectivity during
SARS-CoV amplification. In addition, a study by Hsueh et
al. showed that the viral load rapidly declines at 9 or 10 days
after SARS onset(13). Thus, molecular diagnosis is only suitable for early detection. It is difficult to estimate the initial
onset of SARS infection based on clinical symptoms(13).
Hence, clinics need more effective diagnostic tools for SARS
detection. A study by Drosten et al. showed that patients
with acute SARS-CoV infection had virus-specific IgG
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seroconversion(14). The specificity and sensitivity of SARS
detection can reach > 90% by using SARS-CoV structural
proteins, derived from mammalian cells or Escherichia coli,
as antigens for the detection of anti-SARS-CoV IgG and IgM
in enzyme-linked immunosorbent assays (ELISAs)(15-17). In
addition, reports indicate that the specificity and sensitivity
of serological diagnostic methods can be improved to nearly
100% by using a combination of viral S, M, and N proteins
for detection(13). As demonstrated in these studies, peptide
fragment recognition is commonly used in the development
of serological diagnosis of SARS. However, a reliable reference panel is needed to evaluate the laboratory and clinical
performance of these immunological detection methods. The
SARS reference panel could also be used as a standard for
national authorities to evaluate the effectiveness of SARS
IVDs during the premarket approval process.
The first case of SARS was reported in China in
mid-November 2002, and a global outbreak started in late
February 2003. However, the disease suddenly disappeared
after the last confirmed infection on July 2003, apart from the
subsequent laboratory-acquired infections. At present, little is
known about SARS pathogenesis, and there is yet no effective treatment. An insufficient number of SARS specimens
are available for the development of serological diagnostic
devices. In this study, SARS specimens collected in Taiwan
in 2003 by the Centers for Disease Control of Taiwan (Taiwan
CDC) were used to establish a human anti-SARS serum panel
as a reference standard for SARS diagnosis. The relative titers

of our SARS reference panel were characterized against inactivated whole SARS-CoV, various virus structural proteins,
as well as their peptide fragments. Moreover, the cross-reactivity of this panel with HCoV-229E and HCoV-OC43 was
evaluated by immunofluorescence assay (IFA).

Materials and Methods
I. Materials
Minimum essential medium (MEM), N-acetyl-l-alanylantibiotics (100×, lyophilized), fetal bovine
serum (FBS), and trypsin/ethylenediaminetetraacetic acid
(trypsin/EDTA) solution were purchased from Gibco BRL
(Grand Island, NY, USA). Phosphate-buffered saline (PBS)
was from BioChromAG (Berlin, Germany). Coomassie brilliant blue R-250 was from Sigma-Aldrich (St. Louis, MO,
USA). Specific SARS-CoV ELISA kit and recombinant
viral envelope and nucleocapsid protein were from United
Biomedical Inc. (Taipei, Taiwan) and Serotech Laboratories
Limited (Toronto, Canada), respectively. Goat anti-human
IgG-HRP antibody was from Kirkegaard & Perry Laboratories (Gaithersburg, MD, USA). Mouse anti-coronavirus 229E
monoclonal antibody (clone 401-4A), mouse anti-coronavirus OC43 monoclonal antibody (clone 541-8F), and goat
anti-mouse IgG- Fluorescein isothiocyanate (FITC) antibody
were from Chemicon (MA, USA).

l-glutamine,

Table 1. List of human SARS sera specimens
Serum no.

Serum type

Serum titer

Days after onset at collection

Serum no.

Serum type

1

Positive

1:1,600

119

2

Negative

3

Positive

1:1,600

111

4

Negative

5

Positive

1:1,600

132

6

Negative

7

Positive

1:1,600

119

8

Negative

9

Positive

1:6,400

132

10

Negative

11

Positive

1:1,600

134

12

Negative

13

Positive

1:1,600

121

14

Negative

15

Positive

1:1,600

121

16

Negative

17

Positive

1:1,600

132

18

Negative

19

Positive

1:1,600

135

20

Negative

21

Positive

1:1,600

150

22

Negative

23

Positive

1:6,400

180

24

Negative

25

Positive

1:400

149

26

Negative

27

Positive

1:1,600

133

28

Negative

29

Positive

1:6,400

149

30

Negative

31

Positive

1:6,400

152

32

Negative

33

Positive

1:1,600

139

34

Negative

35

Positive

1:1,600

150

36

Negative

37

Positive

1:1,600

155

38

Negative

39

Positive

1:6,400

125

40

Negative
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II. Specimens Collection
Twenty independent human anti-SARS convalescent
sera [SARS (+)], collected from confirmed SARS patients
during the SARS outbreak in Taiwan by the Taiwan CDC,
were used in this study. Moreover, 20 independent normal
human sera [SARS (-)], obtained from healthy individuals
in Taipei Blood Center before the SARS outbreak, were also
used (Table 1). The average age of 20 healthy donors ranged
from 20 to 40 years old. According to regulations regarding
patient privacy in Taiwan, the SARS patient information,
including age, gender and geography, from the Taiwan CDC
were not disclosed. All SARS (+) sera were inactivated with
gamma irradiation to reduce the potential risk of infection.
The panel was filled with SARS (+)/(-) sera at 0.1 mL per
vial, and samples were stored at -20°C.

mixture of the S, M, and N protein-derived peptides), and
incubated at 37°C for 60 min. The experimental ELISA
protocol followed the operation manual of the specific SARSCoV EIA kit. Distilled water was used as a negative antigen
control. Finally, the O.D. was read at 450 nm. In determining
the variant reactivity of SARS sera against synthetic peptide
fragments, the lower cutoff value for the assays was set by
calculating the mean absorbance value of SARS (-) sera plus
2 standard deviations (SD)(20-21).
(II) Recombinant E and N Proteins
Recombinant full-length E and N proteins (1 μg/μL)
were individually coated on different 96-well plates at 4°C
for 16 h. The experimental ELISA was performed according
to the manufacturer’s protocol.

III. Relative Titers of IgG/IgA/IgM Antibodies in SARS Sera
against Whole SARS-CoV Viral Protein Extracts

V. Relative Titers of IgG Antibody in SARS Sera against
Different SARS-CoV Proteins

The indirect ELISA protocol using inactivated SARSCoV was modified from a previous study(18). Briefly, the
SARS-CoV-infected Vero cells were sonicated in a chilled
cup horn for 10 min and then centrifuged at 10,000 ×g for
5 min at 4°C. The supernatant was inactivated with gammairradiation (20,000 Gy) and used as viral antigen. ELISA
plates (Immulon II HB) were coated with SARS-CoV viral
antigen. Plates were washed 3 times with PBS Tween-20
(PBST), followed by the addition of different dilutions of sera
(1:100-1:6,400) in solutions containing PBST with 5% skim
milk, and incubated at 37°C for 1 h. Plates were washed, and
subsequently, diluted goat anti-human IgG/IgA/IgM horseradish peroxidase conjugate antibody (1:4,000) was added,
and the plates were incubated at 37°C for 1 h. Wells were
washed with PBST 3 times, the peroxidase color reaction
was performed using 2,2’-azino-bis(3-ethylbenzothiazoline6-sulphonic acid) (ABTS) as substrate (KPL, Gaithersburg,
MD, USA) at 37°C for 30 min, and the reaction was terminated using ABTS stop solution. Absorbance was read at
405 nm with a 490-nm reference filter. Antibody titers were
determined at the highest dilution where the positive adjusted
optical density (O.D.) value was ≥ 0.21. For a sample to be
considered positive, the sum-adjusted O.D. (the sum of the
differences between the positive and negative wells) for the
1:100 through 1:6,400 dilutions must exceed 1.25, and the
antibody titer of the sample must be 1:400 or greater.

Different SARS sera were serially diluted from 1:200 to
1:6,400 and individually added to the microplates precoated
with synthetic peptides (S, M, and N peptides) or recombinant E and N proteins. The ELISA protocol was as described
above.

IV. IgG Antibody in SARS Sera against Different SARS-CoV
Proteins
(I) Synthetic S, M, and N Peptide Fragments
The Tor2 SARS-CoV genome sequence was used
to obtain the coding sequences for S, M, and N peptide
synthesis according to the previous study(19). SARS (+) and
SARS (-) sera were diluted 1:200, transferred to the S, M,
and N peptide-coated microplate (containing 2 μg/mL of a

VI. Cross-Reactivity between Different SARS Sera and
HCoV-229E/HCoV-OC43
(I) Cell Culture
The MRC-5 human diploid fibroblast cell line, obtained
from the American Tissue Culture Collection (Manassas, VA,
USA; CCL-171), was maintained in MEM supplemented
with 10% FBS, 100 mg/L streptomycin, and 100 units/mL
penicillin. The culture was incubated at 37°C in a humidified
atmosphere containing 5% CO2. Upon reaching confluence,
cells were washed with PBS, trypsinized with 0.25% trypsinEDTA, washed with fresh culture medium, and transferred
to 6-well plates (1 × 105 cells/mL) for virus infection assays.
(II) Immunofluorescence Assay
Before the assay, MRC-5 cells were trypsinized and
seeded on a 6-well plate (1 × 105 cells/mL) with MEM
containing 2% FBS. Upon reaching confluence, cells were
infected with HCoV-229E (ATCC VR-740) or HCoV-OC43
(ATCC VR-759) at 37°C for 2 h and maintained in MEM with
2% FBS at 37°C in a 95% humidified atmosphere containing
5% CO2 for 3 days. After virus infection, the culture medium
was aspirated and cells were treated with Carnoy’s fixation
solution for 15 min. Fixed MRC-5 cells were treated with
5% normal goat serum and individually reacted with mouse
anti-HCoV-229E, anti-HCoV-OC43 monoclonal antibody,
SARS (+) sera, or SARS (-) sera at 37°C for 2 h. Mouse
anti-HCoV-229E and anti-HCoV-OC43 monoclonal antibodies were used as positive controls. MRC-5 cells without
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HCoV-229E or HCoV-OC43 infection acted as the negative
control. FITC-conjugated goat anti-mouse IgG or anti-human
IgG antibody reacted with MRC-5 cells at a 1:10,000 dilution. Immunofluorescence images were observed under an
Olympus inverted fluorescence microscope (Tokyo, Japan).
(III) Enzyme-Linked Immunosorbent Assay
Virus peptides were extracted from MRC-5 cells infected
with HCoV-229E and used as the antigen for microplate
coating. In brief, the HCoV-229E-infected MRC5- cells were
lysed with radio immunoprecipitation assay (RIPA) solution
on ice. Cell lysate solution was then centrifuged at 13,000
×g for 10 min at 4°C, while the supernatant was collected as
virus peptides. The microplate coating procedure and ELISA
protocol were carried as described above.
VII. Statistical Analysis
Data are presented as the mean and SD. Statistical
significance was determined using Student’s t-test.

Results
Our SARS panel is composed of 20 SARS-positive
sera from convalescent individuals and 20 normal sera from
healthy individuals collected before the SARS outbreak. The
panel was designated as the reference panel for the clinical
evaluation of SARS IVDs by the Taiwan FDA. The analytical results of the tests conducted with this panel would be
used to evaluate SARS IVDs by the Taiwan FDA during the
premarket approval process.
I. Relative Titers of SARS (+) Sera against Whole SARS-CoV
Protein Extracts
To assess the immunological responses of our SARS
(+) sera to SARS-CoV, SARS-CoV protein extracts from
SARS-CoV-infected Vero cells were used to determine the
relative human IgG/IgA/IgM antibody titers. The results
demonstrated that all SARS (+) sera have immunological
titers ranging from 1:1,600 to 1:6,400, except for serum #25
(Table 1). Sera #9, #23, #29, and #31 had the highest immunological reactivity against the whole SARS-CoV protein
extracts, and serum #25 had the lowest reactivity. These
results confirmed that the 20 SARS convalescent sera in our
panel have immunological activities against SARS-CoV.
II. Reactivity of SARS Sera against Synthetic Peptide Fragments and Recombinant Viral Proteins
Since the SARS outbreak in 2003, several types of
SARS ELISA IVDs have been developed using a single
SARS viral protein or viral protein compositions. Various
designs were developed to obtain optimal reaction sensitivity
and specificity. To clarify the immunological response of

different SARS viral proteins against our panel, an ELISA
kit containing commercial synthetic SARS S, M, and N
peptide fragments and an ELISA kit containing recombinant
SARS E or N proteins were used. In the former kit, the assay
plates were precoated with S, M and N peptide fragments for
analysis. In the latter, the assay plates needed to be manually coated with recombinant SARS E or N proteins before
testing.
(I) Synthetic S, M and N Peptide Fragments
The cutoff value for the analysis with synthetic S, M
and N peptide fragments was determined to be 0.332. An
absorbance value higher than the cutoff value was considered
a positive response. The mean signal/cutoff (S/C) ratios for
SARS (+) and SARS (-) sera were 7.477 and 0.731, respectively. The scatter charts of absorbance values with SARS (+)
and SARS (-) sera showed that a total of 18 SARS (+) sera had
positive IgG reactivity against synthetic peptide fragments
(Figure 1A). Only two sera samples, #25 and #27, had no IgG
reactivity with peptide fragments among 20 SARS (+) sera,
so that the sensitivity was 90% (18/20). In addition, only the
negative serum #36 displayed the positive response among
20 SARS (-) sera, while the specificity was 95% (19/20). The
relative titers of sera #25 and #27 against the whole SARSCoV protein extracts were 1:400 and 1:1,600, respectively.
Therefore, a quantitative analysis was performed to calculate
the relative IgG titers against synthetic S, M, and N peptide
fragments. Results showed that sera #9, #29, and #39 had
higher titers (1:3,200), but sera #25 and #27 still had no titer
or had a very low titer (1:50). The other SARS (+) sera had
titers ranging from 1:200 to 1:800.
(II) Recombinant N and E Proteins
The SARS N protein is widely used as a detection target
for serological diagnosis of SARS. Recombinant SARS N
protein was coated on a 96-well plate and reacted with SARS
(+) sera. Figure 1B showed the scatter charts for the absorbance value of the SARS panel against the recombinant N
protein, while the cutoff value was calculated to be 1.183.
Only 12 SARS (+) sera showed positive IgG responses. Eight
of the 20 sera had no IgG reactivity against the recombinant
N protein. In addition, in the quantitative analysis, the relative
IgG titers of the 20 SARS (+) sera against the recombinant
N protein ranged from 1:100 to 1:25,600 (Figure 2). Eight
SARS (+) sera had no IgG reactivity, but their relative titers
were still within the the range of 1:100 to 1:200.
The recombinant SARS E protein was also used to
evaluate IgG titers, with a cutoff value of 0.384. All SARS
(+) sera had positive IgG reactivity (Figure 1C). The mean
S/C ratios for the SARS (+) and SARS (-) sera were 2.284
and 0.861, respectively. Quantitative titers against the recombinant E protein ranged from 1:800 to 1:6,400 (Figure 2).
The immunological responses of the SARS (+) sera against
the recombinant E protein were more consistent than those
against the recombinant N protein.
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III. Cross-Reactivity with HCoV-229E and HCoV-OC43
SARS-CoV is a member of the Coronaviridae family.
HCoV-229E and HCoV-OC43 are human coronaviruses that
commonly cause upper respiratory tract infections. Therefore, the cross-reactivity between SARS-CoV and these two
(A)
3.5
3.0

Optical Density (at 450 nm)

2.5
2.0
1.5
1.0
0.5
0.332

0.0
Serum No.

2 4 6 8 10121416182022242628303234363840

SARS (-)

(B)
(B)

other CoVs should be elucidated. In this study, HCoV-229E
and HCoV-OC43, inoculated into MRC-5 cells, were used
as the reaction targets for the immunofluorescence assay
(IFA). In images obtained under the fluorescence microscope,
5 SARS (+) sera (#9, #23, #29, #31, #39) and 5 SARS (-)
sera, reacted with HCoV-229E-infected cells, showed the
same fluorescence intensity (Figure 3A). Comparison of the
fluorescence signal obtained using the mouse anti-HCoV229E monoclonal antibody with the fluorescence signal
obtained with the SARS (+) sera revealed that the latter was
due to background (non-specific) labeling. In addition, all of
these sera, 5 SARS (+) and 5 SARS (-) sera, reacted with
HCoV-OC43-infected cells and displayed weak fluorescence
signals, which was weaker than our positive control, the
mouse anti-HCoV-OC43 monoclonal antibody (Figure 3B).
Furthermore, ELISA results deduced the absorbance values
of the anti-HCoV-229E antibody, SARS (+) sera, and SARS
(-) sera to be 1.708, 0.616, and 0.616, respectively (Figure
4). These results indicated that our SARS serological panel
exhibited weak cross-reactivity with HCoV-OC43, but has
weak or no cross-reactivity with HCoV-229E.

1 3 5 7 9 111315171921232527293133353739
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Discussion
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One of the most important issues in developing IVDs
is obtaining standard reference materials. Analytical sensitivity and specificity, which are determined using reference
standards or panels, are required for the evaluation of clinical
specimens. A global SARS outbreak suddenly appeared
between late 2002 and mid 2003. This highly contagious
and deadly disease then suddenly disappeared after July 5,
2003 (with the exception of several laboratory-associated
infections)(22). The brevity of the pandemic made specimen
collection extremely challenging, and thus, it was very
difficult to develop SARS diagnostic methods and devices
for academic or industrial use. The Taiwan FDA is a government agency responsible for establishing national standards
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Figure 1. IgG antibody against SARS-CoV synthetic peptide in SARS
sera. Synthetic S, M, and N peptide fragments (A); recombinant N
protein (B); and recombinant E protein (C). ▼: SARS (-) sera; ●: SARS
(+) sera. The dotted line indicates the cutoff value for each group. The
cutoff value was calculated as the mean absorbance value of SARS (-)
sera plus 2 SD.
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Figure 2. Relative titers of IgG antibody in our reference panel against
different SARS-CoV antigens.
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(A)

(B)

Figure 3. Immunofluorescence staining of SARS sera against HCoV-229E-infected (A) and HCoV-OC43-infected MRC-5 cells (B). SARS (-) sera:
#2, #18, #20, #24, and #38; SARS (+) sera: #9, #23, #29, #31, and #39; Positive controls: mouse anti-HCoV-229E monoclonal antibody reacted
with HCoV-229E-infected cells in panel A and mouse anti-HCoV-OC43 reacted with HCoV-OC43-infected cells in panel B, respectively. Negative
controls: MRC-5 cells without HCoV-229E or HCoV-OC43 infection.

and serological reference panels for the control of biological
products. To prepare for a potential future SARS outbreak,
the Taiwan CDC and FDA collaborated to establish a serological SARS reference panel for the clinical evaluation
of newly developed SARS IVDs. The Taiwan FDA has 30
sets of the SARS reference serological panel. This panel is
provided free of charge to biological industries if research
program proposals are submitted for approval by the agency.
In this study, we used different ELISA methods to
evaluate the immunological reactivity of the SARS panel

against recombinant SARS proteins and synthetic peptide
fragments. In addition, Dr. Lia Haynes in the Centers for
Disease Control and Prevention, United States (US CDC),
assisted us in evaluating the immunoactivity of this panel
against the whole SARS-CoV protein extracts. Previous
reports have shown that seroconversion of the IgG/IgA/
IgM antibody occurs at an average of 10 days after infection, and serum levels of this antibody can be detected 210
days after onset(13,23). Hence, we chose the IgG/IgA/IgM
antibody to analyze the immunological response against
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Table 2. Summary of our SARS reference panel against different antigens by IgG relative titers
Relative immunological titers of SARS (+) sera

Antigen for ELISA

＞ 1:3,200 (High)

1:1,600-1:800 (Moderate)

1:400-1:200 (Low)

＜1:100 (None)

9, 23, 29, 31, 39

1, 3, 5, 7, 11, 13, 15, 17,
19, 21, 27, 33, 35, 37

25

-

9, 11, 29, 39

1, 5, 13, 19, 21

3, 7, 15, 17, 23,
31, 33, 35, 37

25, 27

Recombinant E protein

1, 3, 5, 7, 15, 17, 19, 23,
25, 27, 31, 35, 37, 39

9, 11, 13, 21, 29, 33

-

-

Recombinant N protein

5, 9, 13, 17, 19, 25

3, 23

1, 11, 27, 35, 39

7, 15, 21, 29, 31, 33, 37

SARS-CoV extract
Synthetic S/M/N peptide

2.00

Optical Density (at 450 nm)

1.75
1.50
1.25
1.00
0.75
0.50
0.259

0.25
0.00

P

2

18

20

24

SARS (-)

38

9

23

29

31

39

SARS (+)

Figure 4. IgG antibody against HCoV-229E peptide in SARS sera.
Positive control (P, ■): mouse anti-HCoV-229E monoclonal antibody,
▼: SARS (-) sera, ●: SARS (+) sera. The dotted line indicates the
cutoff value, which was calculated as the mean absorbance value of
SARS (-) sera plus 2 SD.

the whole protein extracts of SARS-CoV. The analytical
results obtained using the whole protein extracts may mimic
the immunological responses against SARS-CoV by the
relevant antibodies in the human body. As shown in Table
1, all SARS (+) sera collected between 111 and 180 days
after disease onset were confirmed to be seroconverted.
Because of the diversity of human serum proteins, the relative titers of 20 SARS (+) sera ranged from 1:400 to 1:6,400.
A study by Liu et al. showed that the antigenicity percentage
of SARS-CoV polypeptides in SARS convalescent plasma
ranged from 3.5 to 96.5%(24). We compared antibody titers
against the whole protein extracts, synthetic peptide fragments, and individual recombinant proteins to characterize
the immunological responses of the SARS panel (Table 2).
We found that SARS (+) sera that reacted with whole SARSCoV extracts had an immunological response similar to those
reacted with synthetic S, M and N tripeptide fragments. In
this study, Tor2 sequence was used to synthesize the antigen
fragments because Tor2 sequence was firstly sequenced from
the clinical specimen and mostly used for diagnosis. In 2003,
a study by Marco et al. sequenced the 29,751-base genome

of SARS-associated coronavirus, which was isolated from a
fatal SARS patient belonging to the original case cluster from
Toronto, Canada. After that, many reports discussed about the
Tor2 sequences(25,26). Our result indicates that the synthetic
S, M and N peptide fragments, derived from Tor2 SARS-CoV
genomic coding sequences, are adequate ELISA targets for
serological diagnosis of SARS(19). However, further investigation is required to identify the optimal composition of viral
peptide fragments for the detection of SARS antibodies.
The nucleocapsid protein is the predominant viral structural protein and is shed in large amount into serum, nasopharyngeal aspirate, throat wash samples, fecal matter and
urine during the early days of infection. A study by Che et al.
demonstrated successful detection of SARS-CoV N protein in
various body fluids using specific monoclonal antibodies(27).
The immunodominant epitopes of N protein are already used
in ELISA, IFA, enhanced chemiluminescence immunoassay,
and Western blotting(28). A study by Suresh et al. showed that
SARS-CoV N protein can be detected during the acute phase
of SARS infection(29). However, we found that the IgG titers
of SARS (+) sera against individual N proteins were different
from those against the whole viral protein extracts. At least 7
SARS (+) sera had no IgG reactivity against N protein. This
may be due to the fact that our convalescent SARS (+) sera
were collected > 110 days after disease onset. A study by
Nicholls et al. showed that viral replication and the amount
of SARS-CoV nucleocapsid rapidly decreased after the first 2
weeks of infection(30). This may explain why the recombinant
N protein exhibited the poorest immunoactivity in their study.
Viral envelope proteins are also used for SARS detection with monoclonal antibodies(31). In our study, SARS (+)
sera showed stronger immunoactivity against individual viral
E proteins than against N proteins. On the basis of our findings, we suggest that our SARS panel may be suitable for
evaluating the performance of SARS confirmatory IVDs.
SARS diagnosis can be divided into 2 parts: early detection
and disease confirmation. Patients suspected to have SARS
are first screened using early detection kits, and then those
with a positive SARS response are managed with suitable
medical treatments. SARS is a highly contagious disease.
All patients suspected to have SARS have to be quarantined.
SARS confirmatory IVDs could be used to confirm SARSCoV infection in these patients. Through a combination of
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early detection and disease confirmation, nosocomial SARS
infection can be prevented. Our SARS serological panel is
adequate for assessing SARS confirmatory IVDs and is a
valuable tool for the rapid identification of SARS patients.
There were 4 major strains of human coronaviruses
worldwide. Among them, HCoV-229E and HCoV-OC43 were
found in the 1960s, while HCoV-NL63 and HCoV-HKU1 were
found after the SARS epidemic. Based on the phylogeny of
CoVs RNA-dependent RNA polymerase gene, HCoV-229E
and HCoV-NL63 are classified as group 1b coronaviruses,
while HCoV-OC43 and HCoV-HKU1 are classified as group
2a coronaviruses. SARS-CoV is classified into group 2b(32).
Research has shown that antigenic cross-reactivity is found
between SARS-CoV and other CoVs. Furthermore, a study
by Chan et al. revealed that most SARS patients or healthy
blood donors have preexisting antibodies to CoVs(17,23).
Hence, we chose HCoV-229E from group 1 and HCoVOC43 from group 2 for the cross-reactivity analysis of our
SARS panel. Our results demonstrated that HCoV-229E had
negligible or very weak cross-reactivity with SARS (+) sera,
as determined by IFA and ELISA. However, HCoV-OC43
displayed weak cross-reactivity with SARS (+) and SARS
(-) sera (Figure 3B). A study by Chan et al. showed that the
12 of 20 SARS patients (60%) had 4-fold elevated antibody
titers against HCoV-OC43 or HCoV-229E, or both. In addition, SARS-CoV antibody responses were positively correlated with the increasing titers of preexisting HCoV-229E,
HCoV-OC43, and HCoV-NL63 antibodies(22). Furthermore,
3 HCoV-229E positive patients and 11 HCoV-OC43 positive
patients with no prior exposure to SARS-CoV displayed no
cross-reacting antibody responses to SARS-CoV. Therefore,
the likely reason for the cross-reactivity of our SARS panel
is that our SARS sera had very weak or no immunological
memory toward HCoV-229E, but contain preexisting antibodies against HCoV-OC43(17). Taken together, the results
suggested that our SARS panel, using SARS antibody detection, may provide a relatively specific assay for the development of SARS IVDs, even if the sera from SARS patients
possess weak cross-reactivity with HCoV-OC43.
Although there has been no native SARS infection since
2004, preparedness for a potential future SARS pandemic
might have the same relevance as pandemic flu preparedness. We established a SARS serological panel and examined its immunological characteristics against different types
of SARS viral proteins. One set of the SARS panel was
provided to a diagnostic biotechnology company in Boston
in the United States for SARS diagnostic evaluation in 2006.
The preliminary values obtained for analytical sensitivity and
specificity ranged from 94 to 100% and 84 to 100%, respectively (data not shown). Our SARS serological panel was also
provided to the US CDC for SARS coronavirus diagnostic
and antibody kinetic studies(33). Because only few SARS
serological panels have been established, our SARS panel is
important and useful for clinical, epidemiological, and public
health research.
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